Posts Tagged CMC Market Outlook

CDMOs Buttressed by Resilient Emerging Biopharma Sector

by

Publicly traded emerging biopharmaceutical companies increased their research and development (R&D) expenditure in the second quarter of 2017, reaching almost $3.9 billion, 45% greater than the spending level seen in the second quarter of 2015 (see Figure 1, below). Although the total R&D expenditure of emerging biopharma companies (around $15 billion annually) is a fraction […]

Learn more

Bio/Pharma Financing and Drug Approvals Bounce Back in 2017

by

The bio/pharma sector enjoyed a healthy first half of the year, as several key metrics rebounded strongly from a disappointing 2016. The sector raised $18.1 billion in the first six months of the year, more than double the figure seen for the same period last year, although 12% lower than the record amount recorded in […]

Learn more

Contract Manufacturing Through the Years

by

How has the bio/pharmaceutical contract manufacturing industry evolved over the years and what does the future hold? The 40 years during which Pharmaceutical Technology has served the bio/pharmaceutical industry have been years of momentous growth and change in the way drugs are discovered, developed, manufactured, and sold. Contract development and manufacturing organizations (CDMOs) have long […]

Learn more

AMRI Sold to PE Firms

by

Albany Molecular Research Inc. (AMRI) is being taken private in a deal that values the company at $922 million. The buyers, private equity firms The Carlyle Group and GTCR, are newcomers to the contract development and manufacturing organization (CDMO) space, although Carlyle also owns clinical contract research organization (CRO) PPD Inc. The investors are paying […]

Learn more

Growing Mexico Is Home to Solid CMO Population

by

Proximity to the US, a strong regulatory scheme, affordability and decades-long relationships forged with the help of the North American Free Trade Agreement (NAFTA) are among the factors that may make Mexico an attractive location for contract manufacturing services, particularly for products sold in the US or Latin American markets. The country is also fairly […]

Learn more

Big Pharma Capex Continues to Grow, but Rate Slows

by

Spending by global bio/pharmaceutical companies on new plant and equipment grew by an average of 2.7% in 2016, compared to sales growth of 4.4% (see Figure 1, below). This is the first year in recent times that revenue growth has outpaced capex growth. Moreover, the increase in capital expenditure represented a significant decline from the […]

Learn more

CMOs and CROs Have Different Trajectories

by

CMOs may be gaining as strategic partners to large bio/pharma companies, but they have a much harder path to navigate. A growing number of observers, including the Wall Street analysts that follow the publicly-traded contract research organizations (CROs) and contract manufacturing organizations (CMOs), have made statements recently suggesting that the CMO industry is following the […]

Learn more

2016 Results Summary: A Rising Tide Lifts All Contract Service Boats

by

The Contract Development and Manufacturing Organization (CDMO) sector enjoyed a strong 2016, with all components reporting robust, albeit uneven, growth. Early-stage companies posted especially impressive results, bolstered by generous external funding, and the API sector continued its recent recovery, especially in the small molecule space (see Figure 1, below). The impressive top line results do, […]

Learn more

Strong Economic Growth Draws Pharma Companies to Malaysia

by

A rapidly growing pharma market and environment friendly to clinical trials are among the features that are attracting a growing number of multinational pharmaceutical companies to Malaysia. However, those pluses are balanced by decided favoritism toward domestic production, seen in government supply contracts and tax codes. According to a September 2016 report by PharmSource’s colleagues […]

Learn more